Global pharmaceutical giant Eli Lilly is reportedly in advanced discussions to acquire psychedelic drug developer AtaiBeckley, in what would become the most significant corporate transaction yet seen in the modern psychedelic medicine industry. According to Reuters, citing Bloomberg News and people familiar with the matter, a deal could be announced as early as this week. […]
Already subscribed? Log in
US-listed BioAdaptives, Inc. (OTCID: BDPT) has signed a definitive agreement to acquire Xycota Biosciences LLC, a privately held biotechnology company developing experimental psychedelic medicines for psychiatric and neurological...
Canadian biotechnology company PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has signed an agreement with Corealis Pharma Inc., a contract development and manufacturing organisation based in Laval,...
Definium Therapeutics (NASDAQ: DFTX) is set to present findings from three positive Phase 3 clinical trials of its LSD-based drug candidate, DT120 ODT, at the 2026 Neuroscience Education...
New preclinical findings suggest EB-003 can alter brain activity without producing some of the adverse neurological effects observed with DMT in mice. Enveric Biosciences (NASDAQ: ENVB) has reported...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
